GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stomach cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called HLX43 in 60 people with advanced stomach or gastroesophageal junction cancer that has spread. The drug targets a protein on cancer cells to deliver a toxin directly. The goal is to find the best dose and see if it shrinks tumors safely.
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
New hope for Hard-to-Treat cancers: experimental drug PT886 enters human trials
Disease control Recruiting nowThis study tests a new drug called PT886 in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of PT886 alone, then testing it combined with chemotherapy or immun…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for stomach cancer: combo therapy enters late-stage trial
Disease control Recruiting nowThis study tests a new drug, utidelone capsule, combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. About 778 adults will take part to see if the combination helps them live longer and shrinks …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC